0
Blood based biomarkersWhy do we want them? Exactly what do we want? How will we get it ?
Adapted from Sperling et al (2011) Alzheimer’s and dementia 7 280-92Why do we want (blood based) biomarkers ?
-1.00.60.21.41.8RelativeopticaldensityP<0.050.0 0.2 0.4 0.6 0.8 1.01 - Specificity0.00.20.40.60.81.0SensitivityROC CurveCo...
Biomarkers for prediction‘Conversion’, progression and sub-typeCompanion biomarkersSpecific to target/therapyBiomarkers fo...
Correlation with cortical atrophyCorrelation with cognition (MMSE)Correlation with speed of declineDesign mattersIn man….W...
European Medical Information FrameworkVision: To enable and conduct novel researchinto human health by utilising human hea...
EMIF – a public private partnership for data-integrationEMIF-MetabolicEMIF-ADData PrivacyAnalytical toolsSemantic Integrat...
Maudsley BRCInformatics teamMartina SattleckerSteven KiddleSteve NewhouseAnbarasu LourdasamySimon FurneyGerome BreenRob St...
Upcoming SlideShare
Loading in...5
×

Alz forum lovestone (short)

2,720

Published on

Published in: Technology, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
2,720
On Slideshare
0
From Embeds
0
Number of Embeds
13
Actions
Shares
0
Downloads
7
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Alz forum lovestone (short)"

  1. 1. Blood based biomarkersWhy do we want them? Exactly what do we want? How will we get it ?
  2. 2. Adapted from Sperling et al (2011) Alzheimer’s and dementia 7 280-92Why do we want (blood based) biomarkers ?
  3. 3. -1.00.60.21.41.8RelativeopticaldensityP<0.050.0 0.2 0.4 0.6 0.8 1.01 - Specificity0.00.20.40.60.81.0SensitivityROC CurveComplement Factor H (CFH)n>500Proof of a signal in blood(also complement c4 – decreased)
  4. 4. Biomarkers for prediction‘Conversion’, progression and sub-typeCompanion biomarkersSpecific to target/therapyBiomarkers for pathologyDiscovery by endophenotypeBiomarkers for clinical trialsStratification and experimental medicineWhat, exactly, do we want ?Biomarkers for ADnot needed, not possible
  5. 5. Correlation with cortical atrophyCorrelation with cognition (MMSE)Correlation with speed of declineDesign mattersIn man….W/T APP/PS1In mouse….
  6. 6. European Medical Information FrameworkVision: To enable and conduct novel researchinto human health by utilising human health dataat an unprecedented scale• Access to information on 40 million patients• Cohorts with samples, imaging and clinical data :• > 20,000 for dementia and metabolic biomarker discovery and validation• Linkage of clinical and omics data• Development of a secure (privacy, legal) modular platform• Continue to build a network of data sources and relevant researchhttp://www.imi.europa.eu/content/emifHow will we get biomarkers ?
  7. 7. EMIF – a public private partnership for data-integrationEMIF-MetabolicEMIF-ADData PrivacyAnalytical toolsSemantic IntegrationInformation standardsData access / mgmtIMI Structure and NetworkResearch TopicsEMIF governancePreventionalgorithmsPredictivescreeningRiskstratificationCall 5Call 5RiskfactoranalysisPatientgenerateddataTBDEMIF-PlatformMetabolic CNS
  8. 8. Maudsley BRCInformatics teamMartina SattleckerSteven KiddleSteve NewhouseAnbarasu LourdasamySimon FurneyGerome BreenRob StewartMike DenisRichard DobsonKing’s College LondonBiomarkers teamAbdul HyeJoanna Riddoch-ContrerasRufina LeungAndreas GuentertMohammed AiyazMadhav Thambisetty (NIA)Katie LunnonAlison BairdNicholas AshtonSarah WestwoodLatha VelayudhanChantal BazenetAngela HodgesSimon LovestoneAddNeuroMedImaging teamEric WestmanSebastian MuehlboeckSergi CostafredaLars-Olof WahlundChristian SpengerAlan EvansAndrew SimmonsAddNeuroMedClinical teamHilkka SoininenBruno VellasPatrizia MeccocciMagda TsolakiIwona KłoszewskaSimon Lovestone
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×